These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 12868354

  • 1. [At last new light for the treatment of amyloidosis].
    Pettersson T.
    Duodecim; 2003; 119(12):1097-8. PubMed ID: 12868354
    [No Abstract] [Full Text] [Related]

  • 2. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.
    Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594
    [Abstract] [Full Text] [Related]

  • 3. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
    Lemstra AW, Eikelenboom P, Meijer EW, van Gool WA.
    Ned Tijdschr Geneeskd; 2002 Sep 14; 146(37):1720-3. PubMed ID: 12357871
    [Abstract] [Full Text] [Related]

  • 4. Drug targets for amyloidosis.
    Kolstoe SE, Wood SP.
    Biochem Soc Trans; 2010 Apr 14; 38(2):466-70. PubMed ID: 20298204
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Amyloidosis].
    Mandema E.
    Verh K Acad Geneeskd Belg; 1988 Apr 14; 50(3):274-91. PubMed ID: 3064482
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
    Maeda S.
    Amyloid; 2003 Aug 14; 10 Suppl 1():17-20. PubMed ID: 14640037
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunohistochemical identification of amyloid, using an anti-human serum amyloid P component (SAP) antibody, is possible in ruminants but not in dogs and cats.
    Hartig W, Leifsson PS, Nielsen OL.
    J Vet Med A Physiol Pathol Clin Med; 2005 Nov 14; 52(9):447-53. PubMed ID: 16268955
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Science and serendipity.
    Pepys MB.
    Clin Med (Lond); 2007 Dec 14; 7(6):562-78. PubMed ID: 18193704
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Larynx amyloidosis.
    Akst LM, Thompson LD.
    Ear Nose Throat J; 2003 Nov 14; 82(11):844-5. PubMed ID: 14661432
    [No Abstract] [Full Text] [Related]

  • 20. Glycosaminoglycans inhibit neurodegenerative effects of serum amyloid P component in vitro.
    Urbányi Z, Forrai E, Sárvári M, Likó I, Illés J, Pázmány T.
    Neurochem Int; 2005 May 14; 46(6):471-7. PubMed ID: 15769549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.